Markus Bangerter

2.6k total citations
39 papers, 1.8k citations indexed

About

Markus Bangerter is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Markus Bangerter has authored 39 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Genetics, 17 papers in Pathology and Forensic Medicine and 17 papers in Hematology. Recurrent topics in Markus Bangerter's work include Lymphoma Diagnosis and Treatment (17 papers), Chronic Myeloid Leukemia Treatments (11 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers). Markus Bangerter is often cited by papers focused on Lymphoma Diagnosis and Treatment (17 papers), Chronic Myeloid Leukemia Treatments (11 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers). Markus Bangerter collaborates with scholars based in Germany, United States and United Kingdom. Markus Bangerter's co-authors include Martin Grießhammer, Florian Moog, Norbert Frickhofen, S N Reske, Albrecht Guhlmann, J. Kotzerke, Elmar M. Merkle, C. G. Diederichs, H. Heimpel and Roman Wennauer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Radiology.

In The Last Decade

Markus Bangerter

37 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Markus Bangerter Germany 17 914 750 521 492 337 39 1.8k
Ralph Naumann Germany 21 1.6k 1.7× 819 1.1× 405 0.8× 588 1.2× 730 2.2× 52 2.9k
S.L. Tucker United States 19 425 0.5× 334 0.4× 235 0.5× 420 0.9× 155 0.5× 39 1.4k
Monica Tani Italy 26 1.7k 1.8× 459 0.6× 453 0.9× 385 0.8× 258 0.8× 105 2.2k
R T Hoppe United States 25 1.2k 1.4× 288 0.4× 299 0.6× 464 0.9× 243 0.7× 47 2.1k
Gerardo Musuraca Italy 20 1.2k 1.3× 295 0.4× 532 1.0× 292 0.6× 203 0.6× 83 1.7k
Mars B. van ’t Veer Netherlands 15 536 0.6× 247 0.3× 284 0.5× 198 0.4× 292 0.9× 36 1.4k
T. Girinsky France 28 1.3k 1.5× 837 1.1× 123 0.2× 925 1.9× 241 0.7× 87 2.9k
Max Wolf Australia 22 1.7k 1.8× 302 0.4× 791 1.5× 275 0.6× 206 0.6× 55 2.1k
Vittorio Stefoni Italy 30 2.3k 2.5× 628 0.8× 609 1.2× 589 1.2× 121 0.4× 133 2.8k
Lorena Appio Italy 4 1.3k 1.4× 285 0.4× 404 0.8× 220 0.4× 123 0.4× 8 1.7k

Countries citing papers authored by Markus Bangerter

Since Specialization
Citations

This map shows the geographic impact of Markus Bangerter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Bangerter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Bangerter more than expected).

Fields of papers citing papers by Markus Bangerter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Bangerter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Bangerter. The network helps show where Markus Bangerter may publish in the future.

Co-authorship network of co-authors of Markus Bangerter

This figure shows the co-authorship network connecting the top 25 collaborators of Markus Bangerter. A scholar is included among the top collaborators of Markus Bangerter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus Bangerter. Markus Bangerter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Stegelmann, Frank, Steffen Koschmieder, Susanne Isfort, et al.. (2019). S1608 RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA: RESULTS FROM THE MPNSG‐0212 COMBINATION TRIAL (NCT01644110). HemaSphere. 3(S1). 740–741. 7 indexed citations
2.
Stegelmann, Frank, Martin Grießhammer, Markus Bangerter, et al.. (2017). COMBINATION THERAPY OF POMALIDOMIDE PLUS RUXOLITINIB IN MYELOFIBROSIS: RESULTS FROM COHORT 1 OF THE MPNSG-0212 TRIAL (NCT01644110). Haematologica. 102. 280–280. 2 indexed citations
3.
Heinrich, Bernhard, et al.. (2015). Chemotherapie: besser als ihr Ruf. MMW - Fortschritte der Medizin. 157(14). 39–44.
4.
Stegelmann, Frank, Markus Bangerter, Florian H. Heidel, et al.. (2015). A Phase-Ib/II Study of Ruxolitinib Plus Pomalidomide in Myelofibrosis. Blood. 126(23). 826–826. 8 indexed citations
5.
6.
Bangerter, Markus. (2009). Cytomorphologic Pitfall of Primary Malignant Melanoma of the Parotid Gland. Acta Cytologica. 53(4). 435–436. 2 indexed citations
7.
8.
Wagner, Martin, Ulrike Seitz, Andreas K. Buck, et al.. (2003). 3'-[18F]fluoro-3'-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease.. PubMed. 63(10). 2681–7. 136 indexed citations
9.
Bangerter, Markus, et al.. (2001). Immunophenotypic analysis of simultaneous specimens from different sites from the same patient with malignant lymphoma. Cytopathology. 12(3). 168–176. 15 indexed citations
10.
Bangerter, Markus, et al.. (2000). Fine Needle Aspiration Cytology in Extramedullary Plasmacytoma. Acta Cytologica. 44(3). 287–291. 25 indexed citations
11.
Grießhammer, Martin, B. Kubanek, H. Heimpel, et al.. (2000). Serum Erythropoietin and Thrombopoietin Levels in Patients with Essential Thrombocythaemia. Leukemia & lymphoma. 36(5-6). 533–538. 11 indexed citations
12.
Bangerter, Markus, Martin Grießhammer, & Lothar Bergmann. (1999). Progress in medical imaging of lymphoma and Hodgkin’s disease. Current Opinion in Oncology. 11(5). 339–339. 12 indexed citations
13.
Moog, Florian, Markus Bangerter, C. G. Diederichs, et al.. (1998). Extranodal malignant lymphoma: detection with FDG PET versus CT.. Radiology. 206(2). 475–481. 227 indexed citations
14.
Bangerter, Markus, Florian Moog, Inga Buchmann, et al.. (1998). Whole-body 2-[18F]-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin’s disease. Annals of Oncology. 9(10). 1117–1122. 185 indexed citations
15.
Grießhammer, Martin, R. Arnold, Markus Bangerter, et al.. (1998). Chronic myeloid leukemia in accelerated phase: treatment results with conventional chemotherapy and allogeneic bone marrow transplantation in 96 patients. European Journal Of Haematology. 61(1). 7–13. 6 indexed citations
16.
Frickhofen, Norbert, Elke Müller, Michael Sandherr, et al.. (1997). Rearranged Ig Heavy Chain DNA Is Detectable in Cell-Free Blood Samples of Patients With B-Cell Neoplasia. Blood. 90(12). 4953–4960. 60 indexed citations
17.
Grießhammer, Martin, et al.. (1997). Aspirin in Essential Thrombocythemia: Status Quo and Quo Vadis. Seminars in Thrombosis and Hemostasis. 23(4). 371–377. 45 indexed citations
18.
Bangerter, Markus, F. Herrmann, Martin Grießhammer, et al.. (1997). The abundant presence of Söderström bodies in cytology smears of fine-needle aspirates contributes to distinguishing high-grade non-Hodgkin's lymphoma from carcinoma and sarcoma. Annals of Hematology. 74(4). 175–178. 13 indexed citations
19.
Moog, Florian, Markus Bangerter, C. G. Diederichs, et al.. (1997). Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.. Radiology. 203(3). 795–800. 229 indexed citations
20.
Drechsler, S., U. Bruntsch, Markus Bangerter, et al.. (1997). Comparison of three tropisetron-containing antiemetic regimens in the prophylaxis of acute and delayed chemotherapy-induced emesis and nausea. Supportive Care in Cancer. 5(5). 387–395. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ralph Naumann Breakdown of academic impact, for papers by S.L. Tucker Breakdown of academic impact, for papers by Monica Tani Breakdown of academic impact, for papers by R T Hoppe Breakdown of academic impact, for papers by Gerardo Musuraca Breakdown of academic impact, for papers by Mars B. van ’t Veer Breakdown of academic impact, for papers by T. Girinsky Breakdown of academic impact, for papers by Max Wolf Breakdown of academic impact, for papers by Vittorio Stefoni Breakdown of academic impact, for papers by Lorena Appio
Rankless by CCL
2026